Premarket Decliner
ANTX An2 Therapeutics20.000.000.0%
Premarket:5.90-14.10 (-70.5%)
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
Business WireMon, 12-Feb 6:45 AM
